Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ASE Technology Holding Co Ltd (ASX) vs Smith & Nephew plc (SNN) Price & Performance

ASE Technology Holding Co LtdTrade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

ASE Technology Holding Co Ltd vs Smith & Nephew plc — how do they compare? ASE Technology Holding Co Ltd trades at $39.6 (market cap $85.75B), while Smith & Nephew plc trades at $29.77 (market cap $12.54B). The key difference: ASE Technology Holding Co Ltd is far larger — about 6.8× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.65%). Which is the better fit depends on your goals.

ASXSNN
Market Cap
$85.75B$12.54B
Sector
TechnologyHealth
52-Week High
$45.12$38.70
52-Week Low
$9.63$28.73
Enterprise Value
$90.15B$15.57B
Dividend Yield
1.08%2.65%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ASE Technology Holding Co Ltd

ASE Technology Holding (ASX) trades at $39.62, up 5.39% today, with strong technical momentum and bullish moving averages. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $0.29 exceeding expectations by 26%. Revenue growth accelerated to $645.39B in 2025, with net income reaching $40.02B. Recent news highlights $10.5B capital expenditure increase for AI semiconductor capacity expansion.

Outlook remains positive with 80% analyst buy ratings and projected 2026 revenue of $711.2B. Key opportunities include AI-driven demand growth and margin expansion, while risks involve high valuation multiples (P/E 47.78) and significant capital expenditure commitments. The stock shows strong institutional interest despite some position adjustments by major funds.

Smith & Nephew plc

Smith & Nephew (SNN) trades at $29.76, down 1.06% with bearish technical signals. The company shows improving fundamentals with revenue growth from $5.8B to $6.2B and net income margin expanding to 10.08% in 2025. Recent Q2 2026 earnings beat expectations but the company lowered full-year revenue guidance from 6% to 4% growth due to U.S. Orthopaedics weakness.

While valuation multiples appear reasonable (P/E 20.41, EV/EBITDA 9.9), the stock faces headwinds from mixed earnings performance and cautious analyst sentiment. The primary investment case hinges on execution in robotics and wound care segments offsetting orthopedic challenges, with downside risk from continued U.S. market softness.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ASE Technology Holding Co Ltd

ASE Technology Holding Co Ltd is a semiconductor assembly and testing firm. The company operates in segments: Packaging, Testing, and Electronic Manufacturing Services. Of these, packaging services contribute the most revenue. It involves packaging bare semiconductors into completed semiconductors with improved electrical and thermal characteristics. The Testing Segment includes front-end engineering testing, wafer probing, and final testing services. In the EMS segment, the company designs manufacture and sells electronic components and telecommunication equipment motherboards. The company is based in Taiwan but garners over half its sales from firms in the United States.

Read more on ASX

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN